MedDataX Logo

Retrospective Analysis of Spray Skin Treats for Severe Burns

NCT ID: NCT06170424

Last Updated: 2023-12-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigated the efficacy of novel approach spray skin for extensive severe burns treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Burns are a global public health problem. This study investigated the efficacy of novel approach spray skin (autologous skin cell suspension combined with split-thickness skin grafting, STSG) for extensive severe burns treatment.

We performed a real-world retrospective analysis of extensive burns patients (\> 50% TBSA) from our hospital last 10 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Morality Skin Graft Complications

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

spray skin, severe burn, microskin grafting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental gourp

The patients who used the autologous skin cell suspension combined with skin grafting.

spray skin

Intervention Type PROCEDURE

The patients who used the autologous skin cell suspension combined with skin grafting.

Control group

The patients who used split-thickness skin grafting.

Control group

Intervention Type PROCEDURE

The patients who used skin grafting.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spray skin

The patients who used the autologous skin cell suspension combined with skin grafting.

Intervention Type PROCEDURE

Control group

The patients who used skin grafting.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with \> 50% TBSA

Exclusion Criteria

* died within 1 week after admission
* admitted to hospital more than 1 week after injury
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhu Jiayuan

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jiayuan Zhu

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital, Sun Yat-Sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYSU-FAH-2019287

Identifier Type: -

Identifier Source: org_study_id